$ACAD News

UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49

Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39

Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37

Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

ACADIA Pharmaceuticals Inc. 2026 Q2 - Results - Earnings Call Presentation

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 Earnings Beat, Stock Rises on Raised Guidance

ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est

ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate

Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout

BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25

Acadia Pharma Secures FDA Fast Track Designation For Remlifanserin For Treatment Of Hallucinations And Delusions Associated With Alzheimer’s Disease Psychosis

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30

Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $35

Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36